Navigating the pandemic has been an all-encompassing, once-in-a-lifetime challenge. Globally, life sciences companies responded with leadership and are emerging stronger. How will life sciences companies continue to respond and what areas can they build resiliency going forward?
The life sciences sector has played a pivotal role amid the COVID-19 pandemic. To cope with the global crisis, traditional competitors partnered to accelerate research and develop the fastest novel vaccine in the history. Governments, health systems, payers, retail pharmacies, and nonprofits are now working collaboratively with the sector to provide widespread distribution and administration.
With the introduction of this ‘new-normal’, digitization is broadening the horizon of new possibilities in the life sciences sector. Redefined workplace environments; the shift in health care delivery; and innovative collaborations to create efficiencies are a few examples that are leading to this unprecedented change supported by technological advancements. While pharmaceutical innovation is saving the world, now is the opportunity for biopharma and medtech companies to sustain this forward momentum.
In our 2021 Global Life Sciences Outlook, we explore the various ways COVID-19 accelerated change within the sector, the changes that are likely to stay, and what can be reimagined and made better. It also explores different scenarios for stakeholders to analyze how these changes can better transform the sector.
Read our 2021 Health Care Outlook to know about the issues driving change in the health care sector and present questions and actions health leaders should consider in the coming year.
Review or download previous life sciences sector outlooks.